Screener
Aardvark Therapeutics, Inc. AARD Q3 2026 earnings
Reported November 12, 2026 · Before market open
EPS-$0.88Miss by $0.16
EPS estimate-$0.72
“We have developed a proposed clinical development plan and look forward to discussing it with the FDA. We remain committed to advancing ARD-101 for patients and families affected by PWS.”
Next report
Date not yet announcedVersus estimates
Diluted EPS
FAQ
- When did Aardvark Therapeutics, Inc. report Q3 2026 earnings?
- Aardvark Therapeutics, Inc. (AARD) reported Q3 2026 earnings on November 12, 2026 before market open.
- What were Aardvark Therapeutics, Inc.'s Q3 2026 revenue and EPS?
- Aardvark Therapeutics, Inc. reported eps of $-0.88 for Q3 2026.
- Did Aardvark Therapeutics, Inc. beat estimates in Q3 2026?
- EPS missed the consensus estimate of $-0.72 by $0.16.
- How did Aardvark Therapeutics, Inc.'s Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps declined 17.3% from $-0.75.
- Where can I find Aardvark Therapeutics, Inc.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-459373) and the 10-Q periodic report (0001193125-26-458957) directly on SEC EDGAR. The filing index links above go to sec.gov.
